TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$6.09
-0.02 (-0.33%)
âŧ
5d:
+2.35%
30d:
+4.46%
90d:
+9.93%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TSHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TSHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $6.09, which is considered fair relative to its 30-day fair value range of $5.64 to $6.33.
Technical Outlook: Technically, TSHA is in a uptrend. Immediate support is located at $5.72, while resistance sits at $6.75.
Market Sentiment: TSHA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+118.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TSHA is in a uptrend. Immediate support is located at $5.72, while resistance sits at $6.75.
Market Sentiment: TSHA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+118.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.64 -
$6.33
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.2% below Wall St target ($13.33)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.64 -
$6.33
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.72
Resistance Level
$6.75
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.80
Wall Street Target
$13.33
(+118.2%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: August 23, 2026 7:56 AM ET
Data refreshes hourly during market hours. Next update: 8:56 AM
Data refreshes hourly during market hours. Next update: 8:56 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sukumar Nagendran
SELL
200000 shares
2026-04-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
